Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vanda and keeping the price target at $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors related to Vanda’s emerging GLP-1 adjunct opportunity and the progress of tradipitant. He highlights the launch of the pivotal Thetis trial testing NEREUS (tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, addressing a well-recognized safety issue that limits use of blockbuster diabetes and obesity drugs.
Selvaraju also underscores that tradipitant has already demonstrated meaningful reductions in GLP-1–related vomiting and nausea in a prior Phase 2 study, reinforcing confidence in the current program. He notes that GLP-1 therapies generate tens of billions of dollars annually and that success in Thetis could position tradipitant as a valuable add-on product, potentially attracting interest from leading players like Eli Lilly and Novo Nordisk, with this upside not yet reflected in his valuation.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 20.7% and a 52.09% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics, Rhythm Pharmaceuticals, and Vanda.